MedTrace Logo

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

NCT05305768 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-31

No results posted yet for this study

Summary

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of Xeomin in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

Conditions

  • Glabellar Frown Lines

Interventions

DRUG

IncobotulinumtoxinA

Injection of glabellar rhytids

Sponsors & Collaborators

  • Merz North America, Inc.

    collaborator INDUSTRY

  • Clinical Testing of Beverly Hills

    lead OTHER

Principal Investigators

  • John Joseph, MD · Clinical Testing of Beverly Hills

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-02-28
Completion
2023-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305768 on ClinicalTrials.gov